Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04374799 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Heparin vs Placebo for Cardiac Catheterization

StatusRecruiting
PhasePhase 3
Started2020-10-05
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 20, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Amendment history

2026-02-18
Study Status, Study Design, Outcome Measures v5
Enrollment target3600→1623
Secondary endpoints5 to 6 entries
Hematoma> 5 cm
Primary endpoints2 to 1 entries
hematoma
2025-08-19
Study Status, Oversight, Contacts/Locations v4
Primary completion date2025-08→2026-08
Completion date2025-12→2026-12
Study sitesdetails revised at 1 of 2 sites
2023-03-16
Study Status v3
Primary completion date2024-08→2025-08
Completion date2024-12→2025-12
2020-10-06
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-10-01→confirmed 2020-10-05
Study sitesdetails revised at 2 of 2 sites
2020-10-01
Study Status, Eligibility v1
Start date2020-08→2020-10-01
Eligibility criteria+6 characters
Inclusion Criteria: diagnostic cardiac catheterization; 5Small Frenchsize sheath; patency of the ulno-palmar circulation Exclusion Criteria: abnormal ulno-palmar circulation. ; Prior radial artery thrombosis; Prior surgery close to the access site; Emergent cardiac catheterization. ; History of HIT or allergy to heparin. ; Patients requiring anticoagulation
2020-05-01
Original filing
Patients undergoing cardiac catheterization will be randomized to 3 groups: no anticoagulant, low dose anticoagulant and high dose anticoagulant.
Trial Details
NCT Number NCT04374799
Lead Sponsor London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Conditions Cardiac Disease
Enrollment 1,623 participants
Start Date 2020-10-05
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-20